DDInter1853 DDInter193
Tretinoin, also known as all-trans-retinoic acid (ATRA), is a naturally occurring derivative of [vitamin A] (retinol). It is an oxidation product in the physiological pathway of vitamin A metabolism. In human circulation, tretinoin is normally found at very low concentrations, approximately 4 to 14 nmol/L. Tretinoin exhibits anti-inflammatory, antineoplastic, antioxidant, and free radical-scavenging activities. It has been used in dermatology for many years to treat various skin conditions ranging from acne to wrinkles [A257474,A258185] and activates nuclear receptors to regulate epithelial cell growth and differentiation.[A257474,A257629,A257609] Tretinoin is given orally to treat acute promyelocytic leukemia and topically to treat skin conditions such as acne.[L45389,L34869,L45384]
Berotralstat is a selective inhibitor of plasma kallikrein used in the prophylaxis of attacks of hereditary angioedema (HAE). It works by blocking the enzymatic activity of plasma kallikrein in releasing bradykinin, the major biologic peptide that promotes swelling and pain associated with attacks of HAE. Berotralstat is strictly used to prevent, but not treat, these attacks. Developed by BioCryst Pharmaceuticals, berotralstat is marketed under the name Orladeyo as oral capsules. Berotralstat was first approved by the FDA on December 3, 2020, as the first once-daily oral therapy to prevent angioedema attacks of HAE in adults and pediatric patients 12 years and older. Berotralstat was approved by the European Commission on April 30, 2021 and by Health Canada on June 06, 2022.
Tretinoin {u} (Compound) binds {v} (Gene) RXRG
RXRG {u} (Gene) is bound by {v} (Compound) Bexarotene
Bexarotene {u} may cause a minor interaction that can limit clinical effects when taken with {v} Berotralstat
Tretinoin {u} (Compound) binds {v} (Gene) RXRB
RXRB {u} (Gene) is upregulated by {v} (Compound) Crizotinib
Crizotinib {u} may lead to a major life threatening interaction when taken with {v} Berotralstat
Tretinoin {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Saxagliptin
Saxagliptin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Berotralstat
Tretinoin {u} (Compound) is included by {v} (Pharmacologic Class) Retinoids
Retinoids {u} (Pharmacologic Class) includes {v} (Compound) Bexarotene
Bexarotene {u} may cause a minor interaction that can limit clinical effects when taken with {v} Berotralstat
Tretinoin {u} (Compound) causes {v} (Side Effect) Headache
Headache {u} (Side Effect) is caused by {v} (Compound) Bexarotene
Bexarotene {u} may cause a minor interaction that can limit clinical effects when taken with {v} Berotralstat
Tretinoin {u} (Compound) causes {v} (Side Effect) Headache
Headache {u} (Side Effect) is caused by {v} (Compound) Saxagliptin
Saxagliptin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Berotralstat
Tretinoin {u} (Compound) causes {v} (Side Effect) Dermatitis contact
Dermatitis contact {u} (Side Effect) is caused by {v} (Compound) Quinine
Quinine {u} may lead to a major life threatening interaction when taken with {v} Berotralstat
Tretinoin {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Regorafenib
Regorafenib {u} may lead to a major life threatening interaction when taken with {v} Berotralstat
Tretinoin {u} (Compound) resembles {v} (Compound) Acitretin
Acitretin {u} may lead to a major life threatening interaction when taken with {v} Bexarotene
Bexarotene {u} may cause a minor interaction that can limit clinical effects when taken with {v} Berotralstat
Tretinoin {u} (Compound) resembles {v} (Compound) Acitretin
Acitretin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Epirubicin
Epirubicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Berotralstat
Tretinoin (Compound) binds RXRG (Gene) and RXRG (Gene) is bound by Bexarotene (Compound) and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Berotralstat
Tretinoin (Compound) binds RXRB (Gene) and RXRB (Gene) is upregulated by Crizotinib (Compound) and Crizotinib may lead to a major life threatening interaction when taken with Berotralstat
Tretinoin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Saxagliptin (Compound) and Saxagliptin may cause a moderate interaction that could exacerbate diseases when taken with Berotralstat
Tretinoin (Compound) is included by Retinoids (Pharmacologic Class) and Retinoids (Pharmacologic Class) includes Bexarotene (Compound) and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Berotralstat
Tretinoin (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Bexarotene (Compound) and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Berotralstat
Tretinoin (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Saxagliptin (Compound) and Saxagliptin may cause a moderate interaction that could exacerbate diseases when taken with Berotralstat
Tretinoin (Compound) causes Dermatitis contact (Side Effect) and Dermatitis contact (Side Effect) is caused by Quinine (Compound) and Quinine may lead to a major life threatening interaction when taken with Berotralstat
Tretinoin (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Regorafenib (Compound) and Regorafenib may lead to a major life threatening interaction when taken with Berotralstat
Tretinoin (Compound) resembles Acitretin (Compound) and Acitretin may lead to a major life threatening interaction when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Berotralstat
Tretinoin (Compound) resembles Acitretin (Compound) and Acitretin may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Berotralstat